Can a shingles vaccine and diabetes drug save insulin cells?
NCT ID NCT07614412
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the shingles vaccine Shingrix and the diabetes drug semaglutide, alone or together, can help preserve the body's ability to make insulin in adults recently diagnosed with type 1 diabetes. The goal is to slow the immune attack on insulin-producing cells and protect them from damage. About 240 adults aged 18 to 50 who were diagnosed within the last 100 days will take part. The main measure is how well the pancreas responds to a meal test after one year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECENT-ONSET TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ministry of Health Medical City
Riyadh, Saudi Arabia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a smart pen take the guesswork out of insulin dosing?
- AI takes the wheel: could a smart algorithm optimize insulin pumps from home?
- Can a common diabetes pill make insulin therapy safer and more effective for type 1 diabetes?
- Real-World test of automated insulin system aims to improve blood sugar control for type 1 diabetes
- Can a wearable sensor help young people with type 1 diabetes tame blood sugar swings?
- Can a smartphone app help teens tame type 1 diabetes?